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Background: There are a lot of unmet needs in patients with triple-negative breast cancer (TNBC). Fenofibrate,
a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, has been used for decades to treat
hypertriglyceridaemia and mixed dyslipidaemia. Recent studies show that it might have anti-tumor effects, however,
the mechanism remains unclear. Here, we assessed the ability of fenofibrate to induce apoptosis of TNBC in vitro and
in vivo and explored involved mechanisms.
Methods: MTT method was used to evaluate the anti-proliferation effect of fenofibrate, and invert microscope to
observe the apoptotic morphological changes. The percentage of apoptotic cells and distribution ratios of cell cycle
were determined by flow cytometric analysis. The related protein levels were measured by Western blot method. The
changes of genes and pathways were detected by gene expression profiling. The tumor growth in vivo was assessed
by MDA-MB-231 xenograft mouse model. Terminal deoxytransferase-catalyzed DNA nick-end labeling (TUNEL) assay
was employed to estimate the percentage of apoptotic cells in vivo. In order to evaluate the safety of fenofibrate, blood
sampled from rat eyes was detected.
Results: We found that fenofibrate had anti-proliferation effects on breast cancer cell lines, of which the first five most
sensitive ones were all TNBC cell lines. Its induction of apoptosis was independent on PPAR-α status with the highest
apoptosis percentage of 41.8 ± 8.8%, and it occurred in a time- and dose-dependent manner accompanied by
up-regulation of Bad, down-regulation of Bcl-xl, Survivin and activation of caspase-3. Interestingly, activation of NF-κB
pathway played an important role in the induction of apoptosis by fenofibtate and the effect could be almost totally
blocked by a NF-κB specific inhibitor, pyrrolidine dithiocarbamate (PDTC). In addition, fenofibrate led to cell cycle arrest
at G0/G1 phase accompanied by down-regulation of Cyclin D1, Cdk4 and up-regulation of p21, p27/Kip1. In vivo,
fenofibrate slowed down tumor growth and induced apoptosis with a good safety profile in the MDA-MB-231
xengograft mouse model.
Conclusions: It is concluded that fenofibrate induces apoptosis of TNBC via activation of NF-κB pathway in a PPAR-α
independent way, and may serve as a novel therapeutic drug for TNBC therapy.
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Breast cancer is the most common malignant cancer in
women globally. Based on different gene expression pro-
files, breast cancer is classified into at least four subtypes
[1]. Triple-negative breast cancer (TNBC) is a special
subtype of breast cancer, which is defined as the absence
of estrogen and progesterone receptor expression as well
as ERBB2 amplification. Therefore, when compared with
other subtypes of breast cancer, TNBC has no response to
endocrine or anti-ERBB2 therapies and systemic chemo-
therapy is the major treatment for those patients after
metastasis. However, there is no standard therapeutic
regimen up to now, and a vast majority of deaths occur in
the first 5 years after treatment [2], making that TNBC as
a whole group still has a poor outcome. Therefore, new ef-
fective and safe drugs are urgently needed to be found.
Fenofibrate is a fibric acid derivative and plays an im-
portant role in lowering the levels of serum cholesterol
and triglyceride and elevating the levels of high density
lipoproteins [3]. It has been used for years to treat severe
hypertriglyceridaemia and mixed dyslipidaemia through
activating of peroxisome proliferator-activated receptor-
α (PPAR-α) [3], which is a specific transcription factor be-
longing to the nuclear receptor superfamily [4].
Recent studies showed that fenofibrate might have anti-
tumor effects, however, the detailed mechanisms were not
fully understood. Although such anti-tumor effects were
present in B-cell lymphoma [5], prostate cancer [6], glio-
blastoma [7], mantle cell lymphoma [8], squamous cell
carcinoma [9], hepatocellular carcinoma [10,11], glioma
[12], melanoma [13,14], lung cancer [13,15], fibrosarcoma
[13], medulloblastoma [16] and endometrial cancer [17],
the effects of fenofibrate on breast cancer, especially on
TNBC had not been reported yet. Murad et al. [18] just
showed that treatment with fenofibrate decreased the
semaphorin 6B gene expression of breast cancer cells,
which had a broad range of functions, from immune re-
sponse and cell migration to angiogenesis and cancer.
A better understanding of the effects and mechanisms
may shed light on the new potential TNBC therapy.
Therefore, we assessed the anti-tumor effects of fenofi-




3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium
bromide (MTT), pyrrolidine dithiocarbamate (PDTC),
fenofibrate and giemsa stain were purchased from Sigma
(St Louis, MO, USA). GW6471 was purchased from
Tocris Bioscience (Ellisville, MO, USA). Beta-Actin, p21,
p27/Kip1, Cyclin D1, Akt1, Phospho Akt1 (pS473),
Phospho Erk1 (pT202) / Erk2 (pT185), NF-κB (p65sub-
unit), IKK-α, IκBα and Phospho-IκBα (pS36) antibodieswere purchased from Epitomics (Burlingame, CA, USA).
Cdk2, Cdk4, Cdk6, p53 (DO-2) and TFIIB (D-3) anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). CyclinB1, Bad (D24A9), Bid, Bcl-2,
Bcl-xl, Survivin (71G4B7), Caspase3, Erk1/2 and Phospho-
IKKα(Ser176)/IKK β(Ser177) antibodies were purchased
from Cell Signaling Technology (Beverly, MA, USA). PE
Annexin V Apoptosis Detection Kit I was purchased from
BD Bioscience (San Jose, CA,USA). Cell cycle staining
solution was purchased from MultiSciences Biotech
(Hangzhou, China). Terminal deoxytransferase-catalyzed
DNA nick-end labeling (TUNEL) assay was from Promega
Corporation (Madison, WI, USA). The gene expression
profile was done by KangChen Biotechnology Company
(Shanghai, China).
Cell culture
Cell lines including SK-BR-3, MCF-7, T47D, HCC1937,
HS578T, MDA-MB-231, MDA-MB-436, BT549, MDA-
MB-453, MDA-MB-468 and MCF-10A cells were pur-
chased from the American Type Culture Collection (ATCC,
Bethesda, MD, USA). All cell lines had been tested and au-
thenticated by ATCC. In brief, morphology and prolifera-
tion of cells were routinely assessed and the identities of
cells were verified by isoenzyme and short tandem repeat
analysis. Cells were also regularly tested for mycoplasma in-
fection. MDA-MB-231HM and MDA-MB-231-B cell lines
were established by our institute according to previously
described method [19]. The MDA-MB-231HM cell line
had a high potential to metastasize to lung and MDA-MB-
231-B cell line was obtained from bone metastases resulting
from MDA-MB-231. All cell lines were used for no more
than 3 months after being thawed.
Breast cancer cell lines were cultured in the ATCC-
recommended media, which were supplemented with 10%
fetal bovine serum. Cells were cultured as a monolayer in
5% CO2 and 95% air in a humidified incubator at 37°C
and collected during their exponential growth phase. Cells
were cultured for 24 hours till attachment before experi-
mental use.
Cell proliferation analysis
Cells were seeded into 96-well tissue culture plates
(Nunclon™) at a density of 3 × 104 cells/mL in a volume
of 180 μL culture media and treated with various condi-
tions for different duration of time. Each well was added
with 20 μL of MTT reagent (0.5 mg/mL) and incubated
at 37°C for 4 hours. Afterwards, the supernatant was
sucked out, and the same volume of dimethyl sulfoxide
(DMSO) was added to each well to dissolve the resulting
formazan crystals at 37°C for 20 min. The optical density
values (OD value) were measured at 490 nm using a
plate reader (BioTek Company). The inhibition ratios for
each treatment condition were calculated by OD values.
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as a half maximal inhibitory concentration (IC50) value.
Cell staining analysis
MDA-MB-231 cells were seeded into 6-well tissue cul-
ture plates (Corning) at a density of 1 × 105 cells/mL in a
volume of 2 mL culture media and treated with fenofi-
brate for 24 hours. The plates were washed with PBS once
and cells were fixed with cold methanol for 10 minutes.
After washed twice with PBS, cells were stained with
Giemsa staining solution, observed and photographed
under the microscope.
Apoptosis analysis
Apoptosis was detected by PE Annexin V Apoptosis
Detection Kit I according to the manual instruction. In
brief, cells were washed with PBS twice and 1 × Binding
Buffer once and then suspended in 1 × Binding Buffer.
Cells were double-stained with PE Annexin V and 7-
AAD for 15 minutes in the dark at room temperature,
and then analyzed by flow cytometry.
Cell cycle analysis
Cells were harvested and washed with cold PBS, and then
fixed with 75% ethanol at −20°C overnight. The fixed cells
were washed with cold PBS twice, added 500 μL DNA
staining solution (including 200 μg/mL RNase A and
20 μg/mL propidium iodide staining solution) and incu-
bated for 30 minutes. Finally, cells were analyzed by flow
cytometry in the presence of the dye.
Western blot analysis
Western blot analysis was performed according to the
method described previously [20]. Briefly, cell lysates were
added and proteins from each group were extracted, sepa-
rated by standard SDS-PAGE and then transferred onto
polyvinylidene difluoride membranes. The membranes
were washed, blocked and incubated with specific primary
antihuman antibodies at 4°C overnight. Afterwards, the
membranes were washed and incubated by horseradish
peroxidase-conjugated secondary antibodies for 1 hours at
room temperature. The signals were visualized by lumi-
nescent image analyzer (ImageQuant LAS4000 mini).
TFIIB [21] and β-actin were detected as a loading control.
Human expression microarray analysis
The total RNA was extracted by TRIzol after harvesting
cells treated with fenofibrate. The Whole Human Genome
Oligo Microarray (4x44K, Agilent Technologies) was done
by KangChen Biotechnology. The data extracted from
Agilent Feature Extraction software (version 11.0.1.1) were
quantile normalized and analyzed by the GeneSpring GX
v11.5.1 software package (Agilent Technologies). The fold
change filtering identified differentially expressed genes.Pathway and gene ontology (GO) analysis were applied
to identify the roles of these differentially expressed
genes playing in biological pathways or GO terms. The
microarray data was accessible through Gene Expression
Omnibus (GEO) [22] series accession number GSE49965
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49965).
Nude mouse xenograft model of human tumor
Six-week-old female BALB/c nude mice (Laboratory
Animal Center of Chinese Academy of Sciences, Shang-
hai Branch) were used. Xenografts were initiated by sub-
cutaneous injection of 2 × 106 MDA-MB-231 cells into
each mouse (n = 10 for each group). Seven days after in-
jection, 200 mg/kg of fenofibrate suspended in 5% sodium
carboxymethylcellulose were given daily via intragastric
administration in treatment group, while the equal volume
of 5% sodium carboxymethylcellulose was administrated
in the control group. The treatment lasted 21 days. The
tumor volume was measured every three days and calcu-
lated in the following formula: length × width × height/2
[23]. At the end of the study, tumors were carefully
removed and the paraffin sections were prepared for
TUNEL analysis. Blood was sampled from the eyes of
all mice and detected. All procedures for animal care
were approved by the Animal Management Committee of
Fudan University.
TUNEL assay
The DeadEnd™ Colorimetric TUNEL System was from
Promega Corporation (USA) and used according to
manufacturer’s instructions.
Statistical analysis
Variance between the groups was analyzed using a two-
tailed t-test. P < 0.05 was considered to be significant.
All statistical analyses were performed using SPSS 16.0
software.
Results
Inhibition of cell proliferation
In order to verify the anti-cancer effects of fenofibrate
on the cell lines representing different molecular sub-
types, twelve breast cancer cell lines and one human
breast epithelial cells, MCF-10A, were treated with feno-
fibrate at different concentrations (0, 6.25, 12.5, 25, 50
and 100 μΜ, DMSO in each group was balanced) for
72 hours. Figure 1A showed that fenofibrate inhibited
the proliferation of the twelve breast cancer cell lines in
a dose-dependent manner, especially of TNBC cell lines,
but had the least effect on MCF-10A cells. The first five
most sensitive ones were all TNBC cell lines, that were
MDA-MB-231, MDA-MB-453, BT549, MDA-MB-436
and MDA-MB-231HM cell lines, and their IC50 for
72 hours were 16.07 ± 4.44 μM, 26.72 ± 10.04 μM, 34.47 ±
Figure 1 Fenofibrate inhibits breast cancer cells proliferation. (A) Fenofibrate was able to inhibit the proliferation of twelve breast cancer
cell lines in a dose-dependent manner, but had the least effect on MCF-10A cells. (B) The 72 h IC50 for each cell line was shown and the first five
most sensitive cell lines to fenofibrate were all TNBC cell lines, that were MDA-MB-231, MDA-MB-453, BT549, MDA-MB-436 and MDA-MB-231HM
cells, and MDA-MB-231 cells were the most sensitive ones. Data represent the means ± SD of three independent experiments. TNBC = triple-negative
breast cancer. (C) A considerable number of MDA-MB-231 cells had morphological changes, including the shrinkage and rounding up of cells when
treated with fenofibate.
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ively, and MDA-MB-231 cells were the most sensitive
ones (Figure 1B). Fenofibrate inhibited the proliferation of
T47D, MCF-7 and SKBR3 cells, however, when com-
pared with TNBC cell lines, they were comparatively
less responsive and their IC50 were all above 80 μM
(Figure 1B). Therefore, we chose MDA-MB-231 cells as a
representative for the subsequent study.
Figure 1C showed that as early as 24 hours after feno-
fibrate treatment at different concentrations (0, 6.25, 12.5,
25, 50, and 100 μM, DMSO in each group was balanced),
the number of MDA-MB-231 cells decreased and morph-
ology was altered with features, that were the shrinkage
and rounding up of cells.
Induction of apoptosis
In order to elucidate the detailed mechanisms of death
induced by fenofibrate in MDA-MB-231 cells, we didfurther experiments. MDA-MB-231 cells were treated
with fenofibrate at different concentrations (0, 12.5, 25,
50, and 100 μM, DMSO in each group was balanced)
for 24 and 48 hours. As shown in Figure 2A and B,
the percentage of apoptotic cells reached 27.6 ± 2.2%
and 41.8 ± 8.8% after 24 and 48 hours incubation with
100 μM fenofibrate, increasing by an almost 6.7- and
8.4-fold respectively when compared with DMSO-treated
cells, suggesting a dose- and time-dependent manner.
Besides MDA-MB-231 cells, fenofibrate induced apop-
tosis of BT549 cells and had little effect on MCF-10A
cells (see Additional file 1A and B).
Next we explored how fenofibrate mediated the apoptosis-
inducing effect on MDA-MB-231 cells. Given that Bad,
BID, related to the apoptosis-promoting process, and
Bcl-xl, Bcl-2, Survivin, related to the apoptosis-inhibiting
process, were key regulators of apoptosis, we investi-
gated the effects of fenofibrate on these protein expressions.
Figure 2 Fenofibrate induces apoptosis of MDA-MB-231 cells. (A, B) Fenofibrate induced apoptosis of MDA-MB-231 cells in a time-
and dose-dependent manner. (C) Western blot analysis confirmed that fenofibrate dramatically up-regulated the expression of Bad and
down-regulated the expressions of Bcl-xl and Survivin and finally induced cleavage of caspase-3, but had no impact on BID and Bcl-2.
(A, C) All the experiments were repeated three times and the representative ones of those results were shown. (B) Data represent
the means ± SD of three independent experiments. Feno = fenofibrate, Con = control, *indicates p < 0.05, **indicates p < 0.01,
***indicates p < 0.001.
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to fenofibrate in various concentrations (0, 12.5, 25 and
50 μM, DMSO in each group was balanced) for 6 hours
and 12 hours were detected by Western blot. On one hand,
Bad was dramatically up-regulated, which might explain
the prominent apoptosis-inducing capacity of fenofibrate.
No significant change of BID was found for both 6 hours
and 12 hours treatments. On the other hand, Bcl-xl and
Survivin were significantly down-regulated, and fenofibrate
had no effect on the Bcl-2 level. Furthermore, we found ac-
tivation of caspase-3 (Figure 2C). All the results provided
supports for our findings. In short, fenofibrate induced
apoptosis of MDA-MB-231 cells through enhancing the
expression of Bad and decreasing the expressions of Bcl-xl
and Survivin, and finally resulting in activation of caspase-3.Cell cycle alteration
To further examine that whether cell cycle arrest was
responsible for proliferation inhibition induced by fenofi-
brate, MDA-MB-231 cells were treated with various
concentrations (0, 6.25, 12.5, 25 and 50 μM, DMSO
in each group was balanced) of fenofibrate for 24 and
36 hours and examined by flow cytometry. The per-
centages of cells at G0/G1 phase were only 47.0 ±
3.0% for 24 hours and 45.9 ± 2.9% for 36 hours in the
control group, and they increased to 63.0 ± 2.4% and
63.3 ± 2.6% respectively when the concentration of fenofi-
brate reached 50 μM and the effect was weaker when
other concentrations were given (Figure 3A and B). The
similar cell cycle arrest was found in MDA-MB-468 cells
(see Additional file 1C).
Figure 3 Fenofibrate alters cell cycle of MDA-MB-231 cells. (A, B) Treatment with fenofibrate led to cell cycle arrest of MDA-MB-231 cells at
G0/G1 phase. (C) Fenofibrate exposure caused a time- and dose-dependent decrease of Cyclin D1 and Cdk4 and increase of p21 and p27/Kip1
while the expressions of p53, Cdk2, Cdk6 and Cyclin B1 remained unchanged. (A, C) All the experiments were repeated three times and the
representative ones of those results were shown. (B) Data represent the means ± SD of three independent experiments. Feno = fenofibrate,
Con = control, *indicates p < 0.05.
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at G0/G1 phase, the whole cell extracts from MDA-MB-
231 cells exposed to fenofibrate of various concentra-
tions (0, 12.5, 25 and 50 μM, DMSO in each group was
balanced) for 6 and 12 hours were detected by Western
blot. In line with our cell cycle results analyzed by flow
cytometry, the expression levels of Cyclin D1 and Cdk4,
which were the G0/G1 phase related proteins promot-
ing cell cycle progress, were decreased in a time- and
dose-dependent manner (Figure 3C), when compared
with DMSO- treated cells. As expected, the levels of p21
and p27/Kip1, whose effects were opposite to that of
cyclin D1 and Cdk4, were increased (Figure 3C). There
were no significant changes of p53, Cdk2, Cdk6 and Cyc-
lin B1. All data demonstrated that treatment with fenofi-
brate led to cell cycle arrest of MDA-MB-231 cells at G0/
G1 phase.Cell proliferation inhibition and apoptosis inducement
independent of PPAR-α
Fenofibrate exerts the effect of lowering the levels of serum
lipids over the activation of PPAR-α. MDA-MB-231 cells
also express PPAR-α [24], so the question whether PPAR-α
mediates anti-tumor effects of fenofibrate on MDA-
MB-231 cells should be answered. GW6471 is a PPAR-α
specific inhibitor with a median inhibitory concentra-
tion of 0.24 μM [25], and it is reported that 1.6 μM
GW6471 inhibited the transcriptional activity of en-
dogenous PPAR-α [10]. Furthermore, Additional file 2
showed that 5 μM GW6471 effectively inhibited the
PPAR-α classic target gene expression of MDA-MB-
231 cells (see Additional file 2 and Additional file 3).
Therefore, 5 μM GW6471 was added to inhibit PPAR-
α. As shown in the Figure 4A, the growth ratio of fenofi-
brate alone (0, 12.5, 25, 50 and 100 μM, DMSO in each
Figure 4 Fenofibrate induces apoptosis via activation of NF-κB pathway in a PPAR-α independent way. GW6471 (5 μM), a PPAR-α
specific inhibitor, did not provide protection from anti-proliferation (A) and apoptosis (B) induced by fenofibrate. Data represent the
means ± SD of three independent experiments. (C) Fenofibrate induced nuclear accumulation of p65 accompanied by increasing the
levels of p-IKKα/β and IKKα and decreasing the level of p-IκBα, but had no impact on IκBα. (D) PDTC (10nM), a specific inhibitor of
NF-κB, efficiently inhibited the nuclear accumulation of p65 induced by fenofibrate. (E) Cell apoptosis induced by fenofibrate was
significantly decreased by co-treatment with fenofibrate and 10nM PDTC (** indicates p < 0.01 relative to fenofibrate treatment group).
Data represent the means ± SD of three independent experiments. (F) Exposure to fenofibrate triggered a decrease in p-Akt1 and
p-Erk1/2, but had no effects on Akt1 and Erk1/2. TFIIB was detected as a loading control of nuclear proteins. β-actin was served as a
loading control of cytoplasmic proteins and whole cell proteins. N.S. = No statistical significance. Feno = fenofibrate.
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with 5 μM GW6471 in 72 hours were 100.00 ± 9.14% vs.
99.90 ± 9.23%, 55.74 ± 5.43% vs. 58.60 ± 4.10%, 48.76 ±
5.16% vs. 41.43 ± 3.66%, 34.97 ± 2.82% vs. 28.92 ± 2.94%,
31.69 ± 3.43% vs. 25.71 ± 2.84% respectively, p > 0.05. In
addition, the percentage of apoptotic cells treated with
50 μM fenofibrate alone vs. 50 μM fenofibrate in com-
bination with 5 μM GW6471 in 24 hours was 21.55 ±
2.47% vs. 20.15 ± 1.34%, p > 0.05 (Figure 4B). The re-
sults above indicated that the drug might mediate the
anti-cancer effects in a way independent of PPAR-α
status.Fenofibrate induces apoptosis through activation of
NF-κB pathway
Since apoptosis induced by fenofibrate was independent
of PPAR-α, further investigation about the apoptosis
mechanism was performed. Given that NF-κB was well
known for its significant role in apoptosis, we detected
the levels of its pathway related proteins and their phos-
phorylation status. NF-κB (p65) is inactive in the cyto-
plasm where it combines with IκB, mainly IκBα, which
is regulated by IKKα/β. Under some stimuli, IκBα is
phosphorylated by IKKα/β, then undergoes ubiquitina-
tion and degradation to release p65. Afterwards, p65
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of target genes. As shown in Figure 4C, in MDA-MB-
231 cells, the nuclear p65, the most abundant form of
NF-κB, increased after fenofibrate treatment (0, 25 and
50 μM, DMSO in each group was balanced) for 24 and
48 hours, accompanied by up-regulation of phosphor-
IKKα/β and IKKα and down-regulation of phosphor-
IκBα in cytoplasm, but IκBα remained unchanged. All
data showed that activation of NF-κB pathway was present
with fenofibrate treatment.
In the next step, we explored that whether activation
of NF-κB pathway contributed to the apoptosis effect
induced by fenofibrate. PDTC is a specific inhibitor of
NF-κB, which blocks the transactivation of NF-κB by sup-
pressing the release of inhibitory subunit IκB from the
cytoplasmic form of NF-κB [26]. As shown in Figure 4D,
in comparison with 50 μM fenofibrate treatment, the nu-
clear p65 decreased under 10nM PDTC treatment alone
or in combination with 50 μM fenofibrate for 48 hours
in MDA-MB-231 cells. As shown in Figure 4E, the
percentages of apoptotic cells were 5.85 ± 5.02% for con-
trol and 3.90 ± 1.84% for the 10 nM PDTC treatment
alone (p > 0.05). However, compared with 50 μM fenofi-
brate treatment alone, it significantly decreased from
20.45 ± 0.92% to 6.50 ± 0.85% when treated with 50 μM
fenofibrate in combination with 10nM PDTC for 24 h in
MDA-MB-231 cells (p < 0.01). These results confirmed
that activation of NF-κB pathway accounted for the apop-
tosis effect induced by fenofibrate.
In addition, we also explored the functions of Akt1
and Erk1/2 pathways in anti-tumor effects of fenofibrate.
Figure 4F showed a down-regulation of phosphorylation
of Akt1 and Erk1/2, but no changes occurred in the total
expressions of Akt1 and Erk1/2 after fenofibrate treat-
ment (0, 12.5, 25 and 50 μM, DMSO in each group was
balanced) for 24 and 48 hours in MDA-MB-231 cells.
Therefore, Akt1 and/or Erk1/2 signaling pathways might
also be involved in the anti-tumor effects of fenofibrate
in MDA-MB-231 cells.
The gene expression profile
To make further investigation of the apoptosis-inducing
effects of fenofibrate, we used the gene expression pro-
file chip to compare the changes between the control
group (0 μM for 24 hours) and fenofibrate treatment
group (50 μM for 24 hours) in MDA-MB-231 cells. As
shown in Figure 5A, the top ten most obvious changes
in GO biological process classification were response to
stress, death, cell death, programmed cell death, apoptosis,
cellular component biogenesis, cellular component assem-
bly, regulation of cell death, regulation of programmed cell
death and regulation of apoptosis, out of which 7 were re-
lated to death, 4 to apoptosis. In the top ten most signifi-
cant down-regulated pathways, cell cycle ranked first andpathway in cancer ranked fourth (Figure 5B). In the top
ten most significant up-regulated pathways, p53 pathway
ranked tenth (Figure 5C). These data was in line with our
results in vitro.
Slowing down tumor growth and induction of apoptosis
in vivo
We further explored the effect of fenofibrate on tumor
growth in vivo. As shown in Figure 6A, the volumes of
tumors in the two groups reached the significant differ-
ence after 15 days of fenofibrate treatment (984.11 ±
59.99 mm3 for control and 578.79 ± 70.44 mm3 for fenofi-
brate on day 15, p < 0.01). The tumor sizes, weight of tu-
mors and the percentage of tumor weight/mice body weight
in the treatment group were significantly smaller than those
of the control group after 21 days of fenofibrate treatment
(2.09 ± 0.16 g vs. 2.94 ± 0.13 g for tumor weight and 8.89 ±
0.64% vs. 12.34 ± 0.52% for the percentage of tumor weight/
mice body weight, p < 0.01, Figure 6B, C, D and E).
In order to confirm that the effect on tumor growth
in vivo was due to apoptosis induced by fenofibrate, the
TUNEL assay was carried out. Compared with the con-
trol group, Figures 6F and G showed that the percentage
of apoptotic cells with treatment increased from 17.84 ±
6.63% to 36.22 ± 0.87% (p < 0.01).
The safety of fenofibrate was also evaluated in vivo. As
shown in the Figure 7A and B, there were no statistical
differences between the control and treatment groups in
body weight (23.80 ± 1.25 g vs. 23.40 ± 1.30 g, p > 0.05),
white blood cells (WBC, 25.76 ± 7.36 × 109/L vs. 16.93 ±
7.08 × 109/L, p > 0.05), hemoglobin (HGB, 169.70 ± 7.04 g/L
vs. 153.78 ± 7.92 g/L, p > 0.05), platelet (PLT, 911.00 ±
249.70 × 109/L vs. 1048.67 ± 163.30 × 109/L, p > 0.05), ala-
nine transaminase (ALT, 129.44 ± 46.12 IU/L vs. 152.77 ±
35.09 IU/L, p > 0.05), aspartate aminotransferase (AST,
629.57 ± 42.23 IU/L vs. 630.21 ± 29.93 IU/L, p > 0.05)
and blood urea nitrogen (BUN,10.41 ± 0.39 mmol/L
vs. 10.44 ± 0.25 mmol/L, p > 0.05), suggesting that fenofi-
brate was safe and had little side effects on hematologic,
hepatic and renal function in vivo. These results showed
that fenofibrate slowed down tumor growth and induced
apoptosis in xenograft mouse model with a good safety
profile.
Discussion
To our best knowledge, the present study first showed
the activity of fenofibrate against TNBC cell lines both
in vitro and in vivo. Our results showed that the in-
volved mechanisms resulted from the convergent effects
on cell apoptosis mediated by NF-κB nuclear transloca-
tion and subsequent transactivation and cell cycle arrest
by fenofibrate treatment.
Caspase plays a central role in the execution of apoptosis,
especially caspase-3, and a variety of apoptotic signaling
Figure 5 Changes of the gene expression profiling. After fenofibrate treatment, (A) the top ten most obvious changes in GO biological
process classification confirmed that fenofibrate could induce apoptosis of MDA-MB-231 cells. (B) Cell cycle pathway ranked first in the top ten
most significant down-regulated pathways. (C) p53 pathway ranked tenth in the top ten most significant up-regulated pathways.
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http://www.biomedcentral.com/1471-2407/14/96would lead to activation of caspase-3 [27]. The increase of
pro-apoptosis Bcl-2 family, such as Bad and BID, decrease
of anti-apoptosis Bcl-2 family, such as Bcl-xl and Bcl-2, and
down-regulation of Survivin [28] led to apoptosis by activa-
tion of caspase-3. Study showed that fenofibrate induced
apoptosis in mantle cell lymphoma followed by caspase-3
activation [8]. The Bcl-2 expression decreased in the expos-
ure of fenofibrate in mantle cell lymphoma and prostate
cancer cells as well [6,8]. However, in the present study, we
detected notable decrease of Bcl-xl and increase of Bad but
no significant changes in Bcl-2. Bad had been shown to
bind more strongly to Bcl-xl than Bcl-2, and it could re-
verse the anti-apoptosis activity of Bcl-xl, but not that of
Bcl-2 [29]. The phosphorylation of Bad by growth-factor-
mediated signaling contributed to the cytoprotective func-
tion of Bcl-xl but not Bcl-2 [30]. These data showed a more
intimate relationship between Bcl-xl and Bad than that
between Bcl-2 and Bad, providing a strong support to
our experimental results. Collectively, fenofibrate dis-
rupts the net balance between pro- and anti-apoptosis in
TNBC and then triggers caspase activation, leading to cell
apoptosis ultimately.
Besides apoptosis, cell cycle arrest induced by fenofi-
brate in TNBC contributed to the anti-proliferation effect.
Interestingly, the expression of p21 increased when thecells were exposed to fenofibrate for 6 hours, however,
the effect disappeared when the exposure time lasted for
12 hours, implicating that the p21-mediated G0/G1 phase
arrest might be an early event. Such G0/G1 phase arrest
was accordance with the reports in prostate cancer [6],
mantle cell lymphoma [8], endometrial cancer [17] and
hepatocellular carcinoma [10]. The gene expression profile
data in our research further confirmed the apoptosis and
cell cycle arrest effects induced by fenofibrate.
The anti-proliferation and apoptosis-inducing effects
of fenofibrate in TNBC were independent on PPAR-α
status, which was also reported in B-cell lymphoma [5],
prostate cancer [31], hepatocellular carcinoma [10], mantle
cell lymphoma [8] and endometrial cancer [17]. How-
ever, the PPAR-α dependent mechanisms were used to ex-
plain the anti-cancer effects of fenofibrate in glioma [12],
glioblastoma [7] and melanoma [14]. This paradoxical
phenomenon might be due to the differences in tumor
types or experimental conditions.
The further investigation shed light on the possible
mechanisms of apoptosis induced by fenofibrate, show-
ing that activation of NF-κB pathway played an import-
ant role. In the presence of fenofibrate, PDTC inhibited
the accumulation of p65 in the nucleus and reversed
the apoptosis effect. It is well known that NF-κB has
Figure 6 Fenofibrate slow down the growth of xenograft model of triple-negative breast cancer by inducing apoptosis. (A) Tumor
volume with days after treatment. The volumes of tumors in the two groups reached a significant difference 15 days after fenofibrate treatment
(** indicates p < 0.01 relative to the control group). (B, C) The tumor sizes in the treatment group were significantly smaller than that of the
control group at the end of the study. (D, E) The tumor weight and the percentage of tumor weight/ mice body weight of the treatment
group were significantly lighter than that of the control group (** indicates p < 0.01 relative to the control group). (F, G) The analysis of
paraffin-embedded human breast cancer tissue from nude mouse models by TUNEL assay. Compared with the control group, TUNEL assay
showed an increased number of apoptotic cells in fenofibrate treatment group (** indicates p < 0.01 relative to the control group).
Feno = fenofibrate, Con = control.
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Consistent with our findings, several studies showed that up-
regulation of NF-κB was associated with cyanide-induced
apoptosis [34], thymocyte apoptosis [35], both paclitaxel-
and doxorubicin-induced apoptosis [36,37], and acted as
anti-oncogene [38,39]. However, there were a few reports
indicating that down-regulation of NF-κB signaling was
observed in fenofibrate-related apoptosis in lung cancer[15] and mantle cell lymphoma [8]. Unlike our experiment,
Liang et al. pretreated cancer cells with TNF-α, which arti-
ficially activates NF-κB signaling [15]. The work by Zak
et al. only showed that fenofibrate could down-regulate the
NF-κB signaling [8]. Combined together, fenofibrate kills
cancer cells possibly via NF-κB signaling status.
Cyto-protective pathways, such as Akt1 and/or Erk1/2
pathways might also be involved in anti-tumor effects of
Figure 7 Fenofibrate has a good safety profile. No obvious treatment-related toxicity in terms of body weight (A), hematopoietic function,
liver function and kidney function of animals (B) was observed. Con = control group, Feno = fenofibrate group, WBC = white blood cells,
HGB = hemoglobin, PLT = platelet, AST = aspartate aminotransferase, ALT = alanine transaminase, BUN = blood urea nitrogen, N.S. = No
statistical significance.
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pathways led to apoptosis and cell cycle arrest [40-42]. It
has been reported that fenofibrate induced attenuation
of Akt and/or Erk1/2 activity in prostate cancer [6], hepa-
tocellular carcinoma [10], melanoma [14], medulloblas-
toma [16] and glioma [12]. Inhibition of angiogenesis and
migration by fenofibrate was related to the decreased Akt
[43,44]. Akt activation might either inhibit apoptosis by
phosphorylation of Bad [45], or lead to cell cycle arrest by
down-regulation of p27/Kip1 [46] and p21 [47]. Inhibition
of PI3K activity, leading to inhibition of Akt, induced G0/
G1 phase cell cycle arrest accompanied by the decreased
expressions of Cyclin D1 and Cdk4 [48]. It had been de-
scribed that cross-talk existed between Akt and Erk cas-
cades [49]. Thus, synergistic effects of Akt and Erk with
fenofibrate treatment might be more potent than either
pathway alone involved.
Last we asked whether the effective drug concentration
found in our experiments was easy to achieve in cancerpatients because the IC50 of fenofibrate for MDA-MB-231
cells seemed to be higher. Willson et al. found that the
human half maximal effective concentration (EC50) of
fenofibrate was about 30 μM, and all PPAR-α agonists
demanded such high micromolar concentration to ac-
tivate PPAR-α ligands, which might explain why high
doses were clinically needed [50]. Therefore, the concen-
tration of fenofibrate used in our study was within the
range achieved in patients with hypertriglyceridaemia and
mixed dyslipidaemia who were treated with common dose
of fenofibrate. A safety issue was another concern. Fenofi-
brate had the least effects on human breast epithelial cells
(Figure 1A and Additional file 1B) and the data from the
xenograft mouse model provided the evidence that such
doses of fenofibrate were safe and had little side effects on
hematologic, hepatic and renal functions.
Unlike other new developing anti-TNBC drugs, fenofi-
brate had been approved by the Food and Drug Administra-
tion for clinical use in patients with hypertriglyceridaemia
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http://www.biomedcentral.com/1471-2407/14/96and mixed dyslipidaemia for decades. Besides, fenofibrate
was renal protective in doxorubicin-induced glomerular
injury [51] and cisplatin-induced proximal tubule cell
death [52]. However, mechanisms of sensitivity differences
among breast cancer molecular subtypes and synergetic
effects of fenofibrate with chemotherapy drugs in TNBC
remain unclear in our study, further research will be para-
mount to unravel the mysteries.
Conclusions
In conclusion, our results showed that fenofibrate was
able to induce apoptosis in vitro and in vivo in TNBC
involving the activation of NF-κB pathway, which might
widen the anti-cancer spectrum of fenofibrate. The safety,
convenience and affordability of fenofibrate make it a
promising cancer therapeutic agent in TNBC.
Additional files
Additional file 1: The effect of fenofibrate on less sensitive breast
cancer cells and human breast epithelial cells. (A) Fenofibrate
induced apoptosis of BT549 cells. (B) Fenofibrate barely induced
apoptosis of MCF-10A cells, which were human breast epithelial cells.
(C) Fenofibrate arrested cell cycle of MDA-MB-468 cells at G0/G1 phase.
The experiments were repeated three times and the representative ones
of those results were shown.
Additional file 2: The inhibition of PPAR-α by GW6471. 5 μM
GW6471 significantly inhibited PPAR-α activity, decreasing the ANGPTL4
expression of MDA-MB-231 cells, which was a PPAR-α classic target gene.
Target mRNA level was normalized to GAPDH mRNA level. The result
was expressed as fold change (±SEM) relative to the control. *P < 0.05,
***P < 0.001. Angiopoietin-like 4 = ANGPTL4, Feno = fenofibrate. For
details of real-time PCR assay, see Methods of Additional files in
Additional file 3.
Additional file 3: Methods of Additional files. The method of
quantitative real-time PCR to measure the ability of GW6471 inhibiting
PPAR-α activity.
Abbreviations
TNBC: Triple-negative breast cancer; PPAR-α: Peroxisome proliferator-activated
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